August 21, 2020
In the middle of a pandemic where antibodies are at the center of prevention and treatment research, the Federal Circuit is weighing a case that could deeply impact how drugmakers can patent biologics, an issue that is not only critical to coronavirus research but to pharma at large.
July 09, 2020
A wave of U.S. Supreme Court petition denials has made 2020 a bit of a letdown for patent attorneys, but there are several high-profile cases on the horizon that could decide the fate of Patent Trial and Appeal Board judges and biosimilars law, and offer more clarity on licensing standard essential patents.